Plain-English translation of NCT07002034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether RE104, given as a single injection under the skin, can help reduce depression and anxiety in people dealing with serious medical conditions like cancer, ALS, multiple sclerosis, Parkinson's disease, or pulmonary fibrosis. The researchers want to see if this medication works better than a placebo (a dummy injection that looks real but has no active medicine). You would receive either a low dose or a higher dose of the medication, and researchers would track how you feel over time.
When people are diagnosed with or managing serious illnesses, it's common to develop depression and anxiety—a condition called adjustment disorder. Current treatments don't work for everyone, and this trial is exploring whether this new medication could offer another option for people struggling emotionally with their medical diagnosis.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection under the skin of either a low dose or high dose of the medication—you won't know which one you're getting. After that, you would have follow-up visits where researchers check how you're feeling, ask questions about your mood and anxiety, and make sure the medication is safe. The study involves clinical interviews and possibly some questionnaires to measure your emotional symptoms over time.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States